Table 3.
Secondary Outcomes by treatment group and gender and estimates of the adjusted longitudinal effect
| Time of Assessment Unadjusted Means |
||||||
|---|---|---|---|---|---|---|
| Secondary Outcome Measure | Baseline Mean (SE) |
2 Months Mean (SE) |
4 Months Mean (SE) |
6 Months Mean (SE) |
Adjusted Effect& (SE) |
|
| Anxiety Status | ||||||
| Standard MI (MI1) | Overall | .55 (.05) | .63 (.05) | .57 (.05) | .48 (.05) | .06 (.28) |
| Men | .51 (.07) | .60 (.07) | .51 (.07) | .44 (.07) | −.01 (.39) | |
| Women | .58 (.07) | .65 (.07) | .62 (.07) | .53 (.07) | .12 (.41) | |
| Intensive MI (MI9) | Overall | .58 (.05) | .67 (.05) | .59 (.05) | .55 (.05) | .13 (.27) |
| Men | .54 (.07) | .59 (.07) | .56 (.07) | .54 (.07) | .08 (.37) | |
| Women | .61 (.07) | .75 (.07) | .62 (.07) | .57 (.07) | .20 (.40) | |
| Depression Status | ||||||
| Standard MI (MI1) | Overall | .55 (.05) | .37* (.05) | .35 (.05) | .36 (.05) | −.16 (.30) |
| Men | .38 (.07) | .27* (.07) | .30 (.07) | .23 (.06) | −.95† (.46) | |
| Women | .38** (.07) | .47 (.07) | .40 (.07) | .49 (.07) | .45 (.40)a | |
| Intensive MI (MI9) | Overall | .58 (.05) | .51 (.05) | .43 (.05) | .43 (.05) | −.67††(.28) |
| Men | .51 (.07) | .50 (.07) | .36 (.07) | .33 (.07) | −.72# (.39) | |
| Women | .63 (.07) | .53 (.07) | .50 (.07) | .53 (.07) | −.64 (.40) | |
| # Days Had Psych Problems | ||||||
| Standard MI (MI1) | Overall | 11.40** (1.11) | 11.76 (1.17) | 11.36 (1.14) | 11.88 (1.27) | .26 (1.30)b |
| Men | 8.55* (1.48) | 9.71 (1.54) | 10.02 (1.67) | 10.98 (1.87) | 1.63 (1.80)b | |
| Women | 14.25* (1.57) | 13.81 (1.73) | 12.62 (1.56) | 12.76 (1.74) | −1.13 (1.88) | |
| Intensive MI (MI9) | Overall | 15.70 (1.08) | 12.50 (1.18) | 12.72 (1.22) | 10.80 (1.08) | −3.67†† (1.27) |
| Men | 12.93 (1.47) | 10.46 (1.63) | 9.60 (1.51) | 7.98 (1.29) | −3.59† (1.73) | |
| Women | 18.63 (1.50) | 14.67 (1.67) | 16.04 (1.84) | 13.74 (1.67) | −3.77† (1.87) | |
Adjusted treatment effect was estimated as the average outcome difference between the separate 2, 4, and 6 month follow-ups and baseline controlling for gender (in overall models), age, number of outpatient sessions attended, number of MI sessions, and time-varying ASI psychiatric severity (except for analyses of ASI psych as the outcome).
Indicates a significant difference, either overall or within gender, between treatment conditions for a specific interview at the .10, .05, .01, .001 level
Indicates a significant adjusted within-treatment effect averaged over time at the .10, .05, .01, .001 level
Indicates a significant difference between adjusted treatment effects across treatment at the .10, .05 level